Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 5.699
Filter
1.
Braz. j. biol ; 84: e250739, 2024. tab
Article in English | LILACS, VETINDEX | ID: biblio-1355896

ABSTRACT

Abstract Several reasons may underlie the dramatic increase in type2 diabetes mellitus. One of these reasons is the genetic basis and variations. Vitamin D receptor polymorphisms are associated with different diseases such as rheumatoid arthritis and diabetes. The aim of this study is to investigate the possible association of two identified mutations ApaI (rs7975232) and TaqI (rs731236). Eighty-nine healthy individuals and Fifty-six Type 2 Diabetic (T2D) patients were investigated using RFLP technique for genotyping and haplotyping as well. The distribution of Apal genotypes was not statistically significant among the control (P=0.65) as well as for diabetic patients (P=0.58). For Taql allele frequencies of T allele was 0.61 where of G allele was 0.39. The frequency distribution of Taql genotypes was not statistically significant among the control (P=0.26) as well as diabetic patients (P=0.17). Relative risk of the allele T of Apa1 gene is 1.28 and the odds ratio of the same allele is 1.53, while both estimates were < 1.0 of the allele G. Similarly, with the Taq1 gene the relative risk and the odds ratio values for the allele T are 1.09 and 1.27 respectively and both estimates of the allele C were 0.86 for the relative risk and 0.79 for the odds ratio. The pairwise linkage disequilibrium between the two SNPs Taq1/apa1 was statistically significant in control group (D = 0.218, D' = 0.925 and P value < 0.001) and similar data in diabetic groups (D = 0.2, D' = 0.875 and P value < 0.001). These data suggest that the T allele of both genes Apa1 and Taq1 is associated with the increased risk of type 2 diabetes. We think that we need a larger number of volunteers to reach a more accurate conclusion.


Resumo Várias razões podem estar subjacentes ao aumento dramático da diabetes mellitus tipo 2. Um desses motivos é a base genética e variações. Os polimorfismos do receptor da vitamina D estão associados a diferentes doenças, como artrite reumatoide e diabetes. O objetivo deste estudo é investigar a possível associação de duas mutações identificadas ApaI (rs7975232) e TaqI (rs731236). Oitenta e nove indivíduos saudáveis ​​e 56 pacientes com diabetes tipo 2 (T2D) foram investigados usando a técnica RFLP para genotipagem e haplotipagem também. A distribuição dos genótipos Apal não foi estatisticamente significativa entre o controle (P = 0,65), bem como para os pacientes diabéticos (P = 0,58). Para as frequências do alelo Taql, o alelo T foi de 0,61, onde o alelo G foi de 0,39. A distribuição de frequência dos genótipos Taql não foi estatisticamente significativa entre o controle (P = 0,26), bem como os pacientes diabéticos (P = 0,17). O risco relativo do alelo T do gene Apa1 é 1,28 e a razão de chances do mesmo alelo é 1,53, enquanto ambas as estimativas foram < 1,0 do alelo G. Da mesma forma, com o gene Taq1, os valores de risco relativo e razão de chances para o alelo T são 1,09 e 1,27, respectivamente, e ambas as estimativas do alelo C foram de 0,86 para o risco relativo e 0,79 para o odds ratio. O desequilíbrio de ligação par a par entre os dois SNPs Taq1 / apa1 foi estatisticamente significativo no grupo de controle (D = 0,218, D' = 0,925 e valor P < 0,001) e dados semelhantes em grupos diabéticos (D = 0,2, D' = 0,875 e valor P < 0,001). Esses dados sugerem que o alelo T de ambos os genes Apa1 e Taq1 está associado ao aumento do risco de diabetes tipo 2. Achamos que precisamos de um número maior de voluntários para chegar a uma conclusão mais precisa.


Subject(s)
Humans , Receptors, Calcitriol/genetics , Diabetes Mellitus, Type 2/genetics , Diabetes Mellitus, Type 2/epidemiology , Saudi Arabia , Case-Control Studies , Polymorphism, Single Nucleotide , Gene Frequency , Genotype
2.
Braz. j. biol ; 83: e242818, 2023. tab, graf
Article in English | LILACS, VETINDEX | ID: biblio-1285628

ABSTRACT

Abstract The study was aimed to assess impact of high fat diet (HFD) and synthetic human gut microbiota (GM) combined with HFD and chow diet (CD) in inducing type-2 diabetes (T2D) using mice model. To our knowledge, this is the first study using selected human GM transplantation via culture based method coupled dietary modulation in mice for in vivo establishment of inflammation leading to T2D and gut dysbiosis. Twenty bacteria (T2D1-T2D20) from stool samples of confirmed T2D subjects were found to be morphologically different and subjected to purification on different media both aerobically and anerobically, which revealed seven bacteria more common among 20 isolates on the basis of biochemical characterization. On the basis of 16S rRNA gene sequencing, these seven isolates were identified as Bacteroides stercoris (MT152636), Lactobacillus acidophilus (MT152637), Lactobacillus salivarius (MT152638), Ruminococcus bromii (MT152639), Klebsiella aerogenes (MT152640), Bacteroides fragilis (MT152909), Clostridium botulinum (MT152910). The seven isolates were subsequently used as synthetic gut microbiome (GM) for their role in inducing T2D in mice. Inbred strains of albino mice were divided into four groups and were fed with CD, HFD, GM+HFD and GM+CD. Mice receiving HFD and GM+modified diet (CD/HFD) showed highly significant (P<0.05) increase in weight and blood glucose concentration as well as elevated level of inflammatory cytokines (TNF-α, IL-6, and MCP-1) compared to mice receiving CD only. The 16S rRNA gene sequencing of 11 fecal bacteria obtained from three randomly selected animals from each group revealed gut dysbiosis in animals receiving GM. Bacterial strains including Bacteroides gallinarum (MT152630), Ruminococcus bromii (MT152631), Lactobacillus acidophilus (MT152632), Parabacteroides gordonii (MT152633), Prevotella copri (MT152634) and Lactobacillus gasseri (MT152635) were isolated from mice treated with GM+modified diet (HFD/CD) compared to strains Akkermansia muciniphila (MT152625), Bacteriodes sp. (MT152626), Bacteroides faecis (MT152627), Bacteroides vulgatus (MT152628), Lactobacillus plantarum (MT152629) which were isolated from mice receiving CD/HFD. In conclusion, these findings suggest that constitution of GM and diet plays significant role in inflammation leading to onset or/and possibly progression of T2D. .


Resumo O estudo teve como objetivo avaliar o impacto da dieta rica em gordura (HFD) e da microbiota intestinal humana sintética (GM) combinada com HFD e dieta alimentar (CD) na indução de diabetes tipo 2 (T2D) usando modelo de camundongos. Para nosso conhecimento, este é o primeiro estudo usando transplante de GM humano selecionado através do método baseado em cultura acoplada à modulação dietética em camundongos para o estabelecimento in vivo de inflamação que leva a T2D e disbiose intestinal. Vinte bactérias (T2D1-T2D20) de amostras de fezes de indivíduos T2D confirmados verificaram ser morfologicamente diferentes e foram submetidas à purificação em meios diferentes aerobicamente e anaerobicamente, o que revelou sete bactérias mais comuns entre 20 isolados com base na caracterização bioquímica. Com base no sequenciamento do gene 16S rRNA, esses sete isolados foram identificados como Bacteroides stercoris (MT152636), Lactobacillus acidophilus (MT152637), Lactobacillus salivarius (MT152638), Ruminococcus bromii (MT152639), Klebsiella aerogenides (MT152640), Bacteroides fragilis (MT152909), Clostridium botulinum (MT152910). Esses sete isolados foram, posteriormente, usados ​​como microbioma intestinal sintético (GM) por seu papel na indução de T2D em camundongos. Linhagens consanguíneas de camundongos albinos foram divididas em quatro grupos e foram alimentadas com CD, HFD, GM + HFD e GM + CD. Camundongos que receberam a dieta modificada com HFD e GM + (CD / HFD) mostraram um aumento altamente significativo (P < 0,05) no peso e na concentração de glicose no sangue, bem como um nível elevado de citocinas inflamatórias (TNF-α, IL-6 e MCP-1) em comparação com os ratos que receberam apenas CD. O sequenciamento do gene 16S rRNA de 11 bactérias fecais obtidas de três animais selecionados aleatoriamente de cada grupo revelou disbiose intestinal em animais que receberam GM. Cepas bacterianas, incluindo Bacteroides gallinarum (MT152630), Ruminococcus bromii (MT152631), Lactobacillus acidophilus (MT152632), Parabacteroides gordonii (MT152633), Prevotella copri (MT152634) e Lactobacillus Gasseri (MT152635D), foram tratadas com dieta modificada / CD) em comparação com as linhagens Akkermansia muciniphila (MT152625), Bacteriodes sp. (MT152626), Bacteroides faecis (MT152627), Bacteroides vulgatus (MT152628), Lactobacillus plantarum (MT152629), que foram isoladas de camundongos recebendo CD / HFD. Em conclusão, esses resultados sugerem que a constituição de GM e dieta desempenham papel significativo na inflamação levando ao início ou/e possivelmente à progressão de T2D.


Subject(s)
Humans , Animals , Rabbits , Diabetes Mellitus, Type 2 , Gastrointestinal Microbiome , Bacteroides , RNA, Ribosomal, 16S/genetics , Prevotella , Bacteroidetes , Ruminococcus , Diet, High-Fat/adverse effects , Dysbiosis , Inflammation , Mice, Inbred C57BL
3.
rev.cuid. (Bucaramanga.2010) ; 13(1): 1-12, 20221213.
Article in Spanish | LILACS, BDENF, COLNAL | ID: biblio-1369125

ABSTRACT

Introducción: La Diabetes Tipo 2 es considerado un problema de salud pública que afecta principalmente a las mujeres, que sumado a una mala adherencia al tratamiento terapéutico y, a una falta de calidad de sueño, aumentan la problemática de salud. Objetivo: Determinar las interrelaciones existentes entre la Calidad de Sueño, la Adherencia al Tratamiento Terapéutico y los valores de HbA1c en Mujeres con DT2, perteneciente a una comunidad de la ciudad de Puebla. Materiales y Métodos: El diseño del estudio fue de tipo descriptivo, correlacional y de corte transversal. La muestra se calculó con un nivel de significancia de .05, un coeficiente de correlación .30 y un poder estadístico del 90%, obteniendo una n=110. Los instrumentos utilizados fueron: una cédula de datos personales, el Índice de calidad de sueño de Pittsburgh (PSQI), el Cuestionario de Adherencia Terapéutica MBG (Martín-Bayarre-Grau) y el dispositivo Eclipse A1c. Resultados: Se encontró una relación negativa y significativa para la calidad de sueño con los niveles de HbA1c (rs=-.355; p=.001); no así para con la variable de adherencia al tratamiento terapéutico. Discusión: La información obtenida concuerda con otros estudios, al reafirmar de manera indirecta, las reacciones bioquimicas que ocurren durante la privación del sueño. Conclusiones: Los resultados descubiertos contribuyen al fortalecimiento científico de enfermería, orientando en la mejora de cuidados, que servirá para el diseño de intervenciones que favorezcan a la salud de las mujeres con Diabetes Tipo 2.


Introduction: Type 2 Diabetes is considered a public health problem that mainly affects women, which, added to poor adherence to therapeutic treatment and a lack of quality sleep, increase health problems. Objective: To determine the existing interrelations between Sleep Quality, Adherence to Therapeutic Treatment and HbA1c values in Women with T2D, belonging to a community in the city of Puebla. Materials and Method: the study design was descriptive, correlational and cross-sectional. The sample was calculated with a significance level of .05, a correlation coefficient of .30 and a statistical power of 90%, obtaining n = 110. The instruments used were: a personal data card, the Pittsburgh Sleep Quality Index (PSQI), the MBG Therapeutic Adherence Questionnaire (Martín-Bayarre-Grau) and the Eclipse A1c device. Results: a negative and significant relationship was found for sleep quality with HbA1c levels (rs = -. 355; p = .001); not so for the variable of adherence to therapeutic treatment. Discussion: The information obtained agrees with other studies, indirectly reaffirming the biochemical reactions that occur during sleep deprivation. Conclusions: the results discovered contribute to the scientific strengthening of nursing, guiding the improvement of care, which will serve to design interventions that favor the health of women with Type 2 Diabetes.


Introdução: A diabetes tipo 2 é considerada um problema de saúde pública que afeta principalmente as mulheres, o que somado a uma má aderência ao tratamento terapêutico e, a falta de qualidade do sono, aumenta o problema de saúde. Objetivo: Determinar as inter-relações entre a qualidade do sono, a adesão ao tratamento terapêutico e os valores de HbA1c nas mulheres com DT2, pertencentes a uma comunidade da cidade de Puebla. Materiais e Métodos: O desenho do estudo foi descritivo, correlacional e transversal. A amostra foi calculada com um nível de significância de 0,05, um coeficiente de correlação de 0,30 e um poder estatístico de 90%, obtendo-se uma n=110. Os instrumentos utilizados foram: um formulário de dados pessoais, o Índice de Qualidade de Sono de Pittsburgh (PSQI), o Questionário MBG para Avaliar Adesão Terapêutica (Martín-Bayarre-Grau) e o dispositivo Eclipse A1c. Resultados: Foi encontrada uma relação negativa e significativa da qualidade do sono com os níveis de HbA1c (rs=-.355; p=.001); este não foi o caso para a variável de aderência ao tratamento terapêutico. Discussão: As informações obtidas concordam com outros estudos, reafirmando indiretamente as reações bioquímicas que ocorrem durante a privação do sono. Conclusões: Os resultados descobertos contribuem para o fortalecimento científico da enfermagem, orientando a melhoria dos cuidados, que servirão para o desenho de intervenções que favoreçam a saúde das mulheres com diabetes tipo 2.


Subject(s)
Humans , Female , Sleep , Women , Glycated Hemoglobin A , Diabetes Mellitus, Type 2 , Treatment Adherence and Compliance
4.
An. Fac. Cienc. Méd. (Asunción) ; 55(2): 18-24, 20220801.
Article in Spanish | LILACS | ID: biblio-1380292

ABSTRACT

Introducción: Las enfermedades cardiovasculares son la primera causa de muerte. El accidente cerebrovascular isquémico es un problema de salud pública. Objetivos: Determinar las características clínicas de los pacientes con accidente cerebrovascular de tipo isquémico admitidos durante el periodo de ventana terapéutica en el Servicio de Urgencias del Hospital de Clínicas en el periodo 2018 - 2020. Materiales y métodos: Estudio observacional, descriptivo, retrospectivo, transversal. Los sujetos fueron los pacientes de sexo masculino y femenino, mayores de 18 años admitidos en la Unidad de Ictus del Servicio de Urgencias del Hospital de Clínicas en el periodo de ventana terapéutica comprendido entre junio del año 2018 y septiembre del año 2020. Resultados: Se incluyó en el estudio 512 pacientes. La media de edad fue 65 ± 12,1 años. El sexo más frecuente fue el masculino con (58,7%) y la mayoría proceden del Departamento Central (61,3%). Los factores de riesgo más frecuentes fueron la hipertensión arterial (83,3%), el sobrepeso (34,7%) y la diabetes mellitus tipo 2 (27,3%). Presentaron infarto moderado (41,8%) y la trombólisis fue realizada en el (16%) de los pacientes. Conclusión: Los pacientes que presentaron accidente cerebrovascular de tipo isquémico admitidos en el periodo de ventana terapéutica fueron en su mayoría del sexo masculino, edad media de 65 años, los factores de riesgo cardiovasculares más frecuentes fueron la hipertensión arterial, el sobrepeso y la diabetes mellitus tipo 2, el infarto moderado fue la más frecuente y escasa cantidad recibieron trombólisis.


Introduction: Cardiovascular diseases are the leading cause of death. Ischemic stroke is a public health problem. Objectives: To determine the clinical characteristics of patients with ischemic stroke admitted during the therapeutic window period in the Emergency Department of the Hospital de Clínicas in the period 2018 - 2020. Materials and methods: Observational, descriptive, retrospective, cross-sectional study. The subjects were male and female patients, over 18 years of age admitted to the Stroke Unit of the Emergency Service of the Hospital de Clínicas in the therapeutic window period between June 2018 and September 2020. Results: Included 512 patients in the study. The mean age was 65 ± 12,1 years. The most frequent sex was male with (58.7%), most of them come from the central department (61.3%). The most frequent risk factors were arterial hypertension (83.3%), overweight (34.7%) and type 2 diabetes mellitus (27.3%). They presented moderate infarction (41,8%). Thrombolysis was performed in (16%) of the patients. Conclusion: The patients who presented ischemic stroke admitted in the therapeutic window period were mostly male, mean age 65 years, the most frequent cardiovascular risk factors were arterial hypertension, overweight and mellitus diabetes type 2, moderate infarction was the most frequent and few received thrombolysis.


Subject(s)
Diabetes Mellitus, Type 2 , Overweight , Ischemic Stroke , Hypertension , Cardiovascular Diseases , Public Health , Risk Factors , Cause of Death , Stroke
5.
An. Fac. Cienc. Méd. (Asunción) ; 55(2): 40-46, 20220801.
Article in Spanish | LILACS | ID: biblio-1380313

ABSTRACT

Introducción: El Síndrome Metabólico es de alta prevalencia en la población adulta y comprende un conjunto de factores de riesgo para el desarrollo de diabetes mellitus tipo 2 y cardiopatía isquémica. Objetivos: Determinar la frecuencia, componentes más frecuentes y la diferencia de las mediciones entre hombres y mujeres de Síndrome metabólico en pacientes jóvenes del ambulatorio de la Primera Cátedra de Clínica Médica del Hospital de Clínicas. Materiales y métodos: Diseño observacional, descriptivo, retrospectivo de corte transversal, que incluyó a pacientes adultos de 18 a 40 años que consultaron en el ambulatorio de la Primera Cátedra de Clínica Médica del Hospital de Clínicas de enero a diciembre de 2019. Se determinaron las variables demográficas (edad, sexo, procedencia), perímetro de cintura, presión arterial, c-HDL, triglicéridos y la glicemia. El Síndrome Metabólico se determinó de acuerdo a las definiciones de la NCEP-ATP III. Resultados: Se incluyeron en el estudio 312 pacientes, la edad media fue de 27,5± 6,2 años, en el sexo masculino fue de 27,4 ± 6,6 años y en sexo femenino de 27,9 ± 6,4 años. El 10,5% de los pacientes cumplieron con los criterios para el diagnóstico de Síndrome Metabólico, de los cuales 60,6% pacientes son del sexo femenino. Los componentes individuales más frecuentes son el perímetro de cintura aumentada y el c-HDL bajo. Conclusión: La frecuencia de Síndrome Metabólico es similar a otro estudio realizado en adultos jóvenes e inferior que, en adultos mayores, más en mujeres que en hombres y los componentes individuales más frecuentes fueron la obesidad y la dislipidemia.


Introduction: Metabolic syndrome is highly prevalent in the adult population and includes a set of risk factors for the development of type 2 diabetes mellitus and ischemic heart disease. Objectives: To determine the frequency, most frequent components and the difference of the measurements between men and women of Metabolic Syndrome in young patients of the ambulatory of the First Chair of Medical Clinic of the Hospital of Clinics. Materials and methods: Observational, descriptive, retrospective cross-sectional design, which included adult patients aged 18 to 40 who consulted in the outpatient clinic of the First Chair of Medical Clinic of the Hospital de Clínicas from January to December 2019. The demographic variables (age, sex, origin), waist circumference, blood pressure, HDL-C, triglycerides and glycemia. Metabolic syndrome was determined according to the NCEP-ATP III definitions. Results: 312 patients were included in the study, the mean age was 27.5 ± 6.2 years, in males it was 27.4 ± 6.6 years and in females 27.9 ± 6.4. years. 10.5% of the patients met the criteria for the diagnosis of metabolic syndrome, of which 60.6% patients are female. The most frequent individual components are increased waist circumference and low HDL-C. Conclusion: Frequency of metabolic syndrome similar to another study carried out in young adults and lower than in older adults, more in women than in men and the most frequent individual components were obesity and dyslipidemia.


Subject(s)
Metabolic Syndrome , Diabetes Mellitus, Type 2 , Dyslipidemias , Clinical Medicine , Risk Factors
6.
Rev. urug. enferm ; 17(1): 1-14, jun. 2022.
Article in Spanish | LILACS, BDENF, BNUY, BNUY-Enf | ID: biblio-1362785

ABSTRACT

El presente artículo describe los resultados de una investigación desarrollada en el año 2019, en el contexto del sistema sanitario uruguayo, sub sector público perteneciente a una red que brinda atención a usuarios portadores de Diabetes Mellitus tipo 2, referente en el tratamiento de esta patología a nivel nacional. Se realizó una evaluación del desempeño del modelo de atención de la misma, a través de la óptica de los usuarios en relación a la atención de salud recibida. Se estableció como objetivo evaluar el desempeño del modelo de atención de dicha policlínica. La investigación utilizó un diseño descriptivo, transversal, con un muestreo aleatorio simple, siendo el universo de 179 usuarios. Se utilizó el Procedimiento para Evaluar el Desempeño de Redes Integradas de Servicios de Salud abordando el componente Modelo Asistencial. Este componente posee varias dimensiones que analizan aspectos tanto de accesibilidad a los servicios, como aspectos de conocimientos que el usuario posee sobre la patología y sus derechos. Los resultados obtenidos no difieren de los arrojados en otro estudio realizado en otra red sanitaria de Uruguay, en donde aplicando el mismo instrumento se destacan la casi ausencia de análisis de situación de salud de la población adscripta, dificultades para el acceso a consultas médicas en general, y en particular con especialistas, sumándosele la ausencia de mecanismos de monitoreo clínico y desconocimiento de los servicios que brinda la red. Como resultado se evidenció una red con un bajo índice de desempeño (0.49 %).Concluyendo que el servicio dista de los estándares de calidad establecidos tanto por el prestador de salud al cual pertenece, como por organismos internacionales. De este modo se establecieron posibles riesgos en relación a la accesibilidad a la atención sanitaria que los usuarios perciben, así como una posible vulneración de sus derechos.


Este artigo descreve os resultados de uma investigação realizada ao longo de 2019, no contexto do sistema de saúde uruguaio, subsetor público. Neste, foi realizada uma avaliação do desempenho do modelo assistencial de uma prestadora pública, por meio da percepção dos usuários em relação ao atendimento recebido. O serviço de saúde atendido pertence a uma rede de saúde que atende usuários com Diabetes Mellitus tipo 2 e que, por sua vez, é referência no tratamento dessa patologia em todo o país. O objetivo foi avaliar o desempenho do modelo assistencial da referida policlínica. A pesquisa utilizou um delineamento descritivo, transversal, com amostragem aleatória simples, em que o universo foi constituído por 179 usuários. Foi utilizado o Procedimento de Avaliação de Desempenho de Redes Integradas de Serviços de Saúde, abordando o componente Modelo Assistencial. Este componente possui várias dimensões que analisam aspectos tanto da acessibilidade aos serviços, quanto aspectos do conhecimento que o usuário possui sobre a patologia e seus direitos. Como resultado, evidenciou-se uma rede com baixo índice de desempenho (0,49 %).


This article describes the results of an investigation carried out throughout 2019, in the context of the Uruguayan health system, sub public sector. In this, an evaluation of the performance of the care model of a public provider was carried out, through the perception of the users in relation to the health care received. The health service addressed belongs to a health network that provides care to users with type 2 Diabetes Mellitus and which, in turn, is a benchmark in the treatment of this pathology at the national level. The objective was to evaluate the performance of the care model of said polyclinic. The research used a descriptive, cross-sectional design, with a simple random sampling, in which the universe consisted of 179 users. The Procedure to Evaluate the Performance of Integrated Health Services Networks was used, addressing the Healthcare Model component. This component has several dimensions that analyze aspects of both accessibility to services, as well as aspects of knowledge that the user has about the pathology and their rights. As a result, a network with a low performance index (0.49 %) was evidenced. It was concluded that the service falls short of the quality standards established both by the health provider to which it belongs, and by international organizations. In this way, possible risks were established in relation to the accessibility to health care that users perceive, as well as a possible violation of their rights as individuals.


Subject(s)
Humans , Uruguay , Evaluation Study , Diabetes Mellitus, Type 2 , National Health Systems , Healthcare Models
8.
Rev. cir. traumatol. buco-maxilo-fac ; 22(1): 17-21, jan.-mar. 2022. ilus
Article in Portuguese | LILACS, BBO | ID: biblio-1391396

ABSTRACT

A mucormicose é uma infecção fúngica angioinvasiva que afeta uma ampla faixa etária, geralmente imunodeprimidos, sem predileção por gênero ou raça e com alta taxa de mortalidade. Essa infecção inicia se no nariz, devido à inalação dos esporos, podendo-se espalhar pelos seios paranasais, órbita e estruturas intracranianas. As características clínicas incluem parestesia perinasal, celulite periorbitária, rinorréia, obstrução nasal, epistaxe e diminuição de peso. O tratamento efetivo dessa comorbidade compoe uma combinação de manejo clínico e medicamentoso, conjuntamente com desbridamento cirúrgico radical do tecido infectado e/ou necrótico. O caso clínico descrito nesse trabalho refere-se a uma paciente diagnosticada com Mucormicose rino maxilar e diabetes do tipo II, a qual foi submetida a procedimento cirúrgico de hemimaxilectomia do lado esquerdo com posterior reabilitação protética para selamento de comunicação buco-naso-sino-etmoidal... (AU)


Mucormycosis is an angioinvasive fungal infection that affects a wide age group, usually immunocompromised, with no gender or race predilection, and with a high mortality rate. This infection starts in the nose, due to the inhalation of spores, and can spread through the paranasal sinuses, orbit and intracranial structures. Clinical features include perinasal paresthesia, periorbital cellulitis, rhinorrhea, nasal obstruction, epistaxis and weight loss. Effective treatment of this comorbidity comprises a combination of clinical and drug management, together with radical surgical debridement of infected and/or necrotic tissue. The clinical case described in this work refers to a patient diagnosed with Mucormycosis Rhinomaxilla and Type II diabetes, who underwent a surgical procedure of left hemimaxillectomy with subsequent prosthetic rehabilitation for sealing of the bucco nasal-sino-ethmoidal communication... (AU)


La mucormicosis es una micosis angioinvasiva que afecta a un amplio grupo de edad, habitualmente inmunodeprimidos, sin predilección de género ni raza, y con una alta tasa de mortalidad. Esta infección comienza en la nariz, debido a la inhalación de esporas, y puede extenderse a través de los senos paranasales, la órbita y las estructuras intracraneales. Las características clínicas incluyen parestesia perinasal, celulitis periorbitaria, rinorrea, obstrucción nasal, epistaxis y pérdida de peso. El tratamiento eficaz de esta comorbilidad comprende una combinación de manejo clínico y farmacológico, junto con un desbridamiento quirúrgico radical del tejido infectado y / o necrótico. El caso clínico descrito en este trabajo se refiere a una paciente diagnosticada de Mucormicosis Rinomaxilar y diabetes Tipo II, que fue sometida a un procedimiento quirúrgico de hemimaxilectomía izquierda con posterior rehabilitación protésica para sellar la comunicación buco-nasal-sino-etmoidal... (AU)


Subject(s)
Humans , Female , Middle Aged , Paranasal Sinuses/surgery , Surgical Procedures, Operative , Diabetes Mellitus, Type 2 , Mouth/surgery , Mouth Rehabilitation , Mucormycosis , Nasal Obstruction , Infections , Mucorales
9.
Más Vita ; 4(1): 104-112, mar. 2022. tab
Article in Spanish | LILACS, LIVECS | ID: biblio-1372135

ABSTRACT

La diabetes Mellitus es un padecimiento que empieza cuando el páncreas no realiza un uso adecuado de la insulina que produce o no puede lograr producir insulina. Se descomponen en glucosa en la sangre todos los alimentos ricos en hidratos de carbono; la insulina da ayuda a la glucosa para que esta pueda ingresar en las células. Los niveles de azúcar en la sangre al no funcionar bien el páncreas suben, lo cual debe ser controlado por medio de un tratamiento médico de por vida, y lo más importante la persona debe cambiar de hábitos en su salud. Objetivo: El objetivo principal de esta investigación es definir el efecto que produce la adherencia a la insulinoterapia en los pacientes con diabetes tipo II del Hospital del Día Mariana de Jesús. Materiales y Métodos: Se utilizó una investigación cuantitativa, transversal ya que se realizó una encuesta a los pacientes, la cual se procedió a la recolección y análisis e interpretación de datos. La muestra trabajada fue de 100 pacientes, los cuales fueron atendidos en el Hospital por concepto de diabetes tipo II en el área de emergencia. Resultados: Como resultado de la investigación tenemos que el 76% de los encuestados conocen sobre el tratamiento de la insulinoterapia, el 85% se rehusó a utilizar insulina cuando inició su tratamiento, el 75% ha tenido dificultad para la conservación de la insulina, el 63% considera que el uso de la insulina es riesgos, el 53% indicó haber recibido asesoría sobre los posibles efectos de la insulina, al 65% de encuestados su jornada laboral no le permite asistir a su control médico, el 72% ha sentido un desmejoro en su salud al dejar el tratamiento y el 63% de los encuestados indicó que ha abandonado en algún momento su tratamiento por temor a los efectos secundarios que dicen tener. Conclusiones: Se estableció el tipo de complicaciones que se dan en los pacientes ante la no adherencia a la insulinoterapia, uno de ellos fue, que al dejar el tratamiento los pacientes sintieron un desmejoro en su estado de salud, así también, los pacientes han abandonado el tratamiento en algún momento por miedo a los efectos secundarios que dicen tener la insulina(AU)


Diabetes Mellitus is a condition that begins when the pancreas does not make proper use of the insulin it produces or cannot achieve produce insulin. All foods rich in glucose are broken down into glucose in the blood. carbohydrates; insulin helps glucose to enter the cells cells. When the pancreas does not work well, blood sugar levels rise, which must be controlled by lifelong medical treatment, and most importantly the person must change their health habits. Objective: The main objective of this research is to define the effect produced by adherence to insulin therapy in patients with type II diabetes at Hospital del Día Mariana de Jesús. Materials and Methods: A quantitative, cross-sectional investigation was used since a patient survey which proceeded to the collection and analysis and interpretation of data. The sample worked was 100 patients who were treated at the Hospital for type II diabetes concept in the emergency area. Results: Like result of the investigation we have that 76% of the respondents know about the insulin therapy treatment, 85% refused to use insulin when they started their treatment, 75% have had difficulty conserving insulin, 63% considers that the use of insulin is risky, 53% indicated having received counseling about the possible effects of insulin, 65% of those surveyed did not care about their working hours. allows them to attend their medical control, 72% have felt a deterioration in their health when leaving the treatment and 63% of those surveyed indicated that they had abandoned their treatment at some point. treatment for fear of the side effects they claim to have. Conclusions: If established the type of complications that occur in patients due to non-adherence to insulin therapy, one of them was that when leaving the treatment the patients felt a deterioration in their state of health, as well as the patients have abandoned the treatment at some point for fear of the side effects that they claim to have insulin(AU)


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Therapeutics , Diabetes Mellitus, Type 2/complications , Insulin , Pancreas/physiopathology , Blood Glucose , Surveys and Questionnaires , Drug Therapy , Life Style
10.
Rev. bras. med. fam. comunidade ; 17(44): 2428, 20220304. ilus, tab
Article in Portuguese | LILACS, ColecionaSUS | ID: biblio-1380389

ABSTRACT

Introdução: Introdução: Diabetes mellitus tipo 2 é um importante e crescente problema de saúde para todos os países. Objetivo: Este trabalho visa avaliar a qualidade da evidência disponível sobre os fármacos inibidores de sódio-glicose 2 e agonistas de glucagon 1 em pessoas com diabetes mellitus e doença cardiovascular aterosclerótica Métodos: Realizou-se revisão integrativa utilizando as bases de dados MEDLINE via PubMed, Embase via Cochrane Library, Cochrane Library, LILACS via BVS. A pergunta de pesquisa foi estruturada da seguinte forma: população ­ pessoas com diabetes mellitus tipo 2 e doença cardiovascular estabelecida; intervenção ­ tratamento usual exceto insulina + inibidores de sódio-glicose 2 ou tratamento usual exceto insulina + agonistas de glucagon 1; controle - tratamento usual exceto insulina + placebo; desfecho ­ mortalidade geral, mortalidade por causas cardiovasculares, morbidade, efeitos adversos. Resultados: Selecionaram-se dois estudos sobre empagliflozina. Esse medicamento associado ao tratamento usual foi superior ao placebo associado ao tratamento usual no desfecho primário (HR 0,86; IC95% 0,74­0,99; p=0,04), na redução de hospitalização por insuficiência cardíaca (HR 0,65; IC95% 0,50­0,85; p=0,002), da mortalidade cardiovascular (HR 0,62; IC95% 0,49­0,77) e da mortalidade geral (HR 0,68; IC95% 0,57­0,82; p<0,001). No subgrupo de pessoas com diabetes que não usavam insulina, houve benefício com empagliflozina em relação ao desfecho primário (HR 0,79; IC95% 0,64­0,97; DR 2,5; NNT 40) e a mortes de causa cardiovascular (HR 0,61; IC95% 0,44­0,85; DR 2; NNT 49). Houve heterogeneidade entre os subgrupos com benefício de empagliflozina no desfecho primário apenas para aqueles com idade ³65 anos (p=0,01) e hemoglobina glicada <8,5 (p=0,01). Em relação às mortes por causas cardiovasculares, houve diferença (p=0,05) com o uso de empagliflozina reduzindo o risco somente no subgrupo com índice de massa corporal <30. Não houve diferença significativa em relação ao placebo para acidente vascular encefálico fatal e não fatal, tampouco no desfecho composto de acidente vascular encefálico debilitante não fatal e acidente vascular encefálico fatal (HR 0,81; IC95% 0,43­1,50; p=0,50). Houve mais pessoas acometidas por acidente vascular encefálico no grupo intervenção em que a hemoglobina glicada inicial era ≥8,5%, favorecendo o placebo (p=0,01). Conclusões: Os dados encontrados favorecem o benefício de utilizar esse medicamento no Sistema Único de Saúde em pessoas com doenças cardiovasculares. Entretanto, houve heterogeneidade entre grupos populacionais, o que pode ajudar a delinear estratégias de uso para esses medicamentos. São necessários mais estudos para avaliar qual seria o motivo de não haver benefício em desfechos cerebrovasculares isoladamente.


Introduction: Introduction: Type 2 diabetes mellitus is an important and growing health problem worldwide. Objective: This study aims to evaluate the quality of the evidence available on sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists in people with diabetes mellitus and atherosclerotic cardiovascular disease. Methods: This integrative review was performed using the following databases: MEDLINE via PubMed, Embase via Cochrane Library, Cochrane Library, LILACS via VHL. The research question was structured as follows: population ­ people with type 2 diabetes mellitus and established cardiovascular disease; intervention ­ usual treatment, except insulin + sodium-glucose cotransporter 2 inhibitors or usual treatment, except insulin + and glucagon-like peptide 1 agonists; control ­ usual treatment, except insulin + placebo; outcome ­ overall mortality, mortality from cardiovascular causes, morbidity, adverse effects. Results: Two studies on empagliflozin were selected. This drug associated with the usual treatment was superior to placebo associated with the usual treatment in the primary outcome (hazard ratio ­ HR 0.86; 95% confidence interval ­ 95%CI 0.74­0.99; p=0.04), in reducing heart failure hospitalization (HR 0.65; 95%CI 0.50­0.85; p=0.002), in cardiovascular mortality (HR 0.62; 95%CI 0.49­0.77), and in overall mortality (HR 0.68; 95%CI 0.57­0.82; p<0.001). The subgroup of people with diabetes who were not on insulin benefited from using empagliflozin concerning the primary outcome (HR 0.79; 95%CI 0.64­0.97; risk difference ­ RD 2.5; number needed to treat ­ NNT 40) and cardiovascular mortality (HR 0.61; 95%CI 0.44­0.85; RD 2; NNT 49). The analysis of the subgroups showed heterogeneity. Participants aged 65 years or older (p=0.01) and those with glycated hemoglobin lower than 8.5 benefited from empagliflozin in the primary outcome. A difference (p=0.05) related to cardiovascular mortality was found, with the use of empagliflozin reducing the risk only in the subgroup with body mass index <30. No significant difference was identified with respect to placebo for fatal and nonfatal stroke nor for the composite outcome of nonfatal disabling stroke and fatal stroke (HR 0.81; 95%CI 0.43­1.50; p=0.50). More people had strokes in the intervention group in which the initial glycated hemoglobin was ≥8.5%, favoring placebo (p=0.01). Conclusions: The data found suggest the benefit of the Brazilian public health system using this drug in people with cardiovascular diseases. However, the population groups were heterogeneous, which may help outline strategies for using these medications. Further studies are necessary to assess why isolated cerebrovascular outcomes showed no benefit.


Introducción: Diabetes mellitus tipo 2 es un importante y creciente problema de salud para todos los países. Objetivo: Este trabajo busca evaluar la calidad de la evidencia disponible sobre los fármacos Inhibidores del Cotransportador de Sodio-Glucosa 2 y agonistas de Péptido 1 similar al glucagón en personas con diabetes mellitus y enfermedad cardiovascular aterosclerótica. Métodos: Se realizó revisión integrativa utilizando las bases de datos MEDLINE vía PubMed, Embase vía Cochrane Library, Cochrane Library, LILACS vía BVS. La pregunta de investigación fue estructurada de la siguiente manera: población ­ personas con diabetes mellitus tipo 2 y enfermedad cardiovascular establecida; intervención ­ tratamiento usual excepto insulina + inhibidores de sodium-glucose cotransporter-2 o tratamiento usual excepto insulina + agonistas de Péptido 1 similar al glucagón; control ­ tratamiento habitual excepto insulina + placebo; desenlace ­ mortalidad general, mortalidad por causas cardiovasculares, morbilidad, efectos adversos. Resultados: Se seleccionaron dos estudios sobre empagliflozina. Este medicamento asociado al tratamiento habitual fue superior al placebo asociado al tratamiento usual en el resultado primario (HR 0.86; IC95% 0.74­0.99; p=0,04), en la reducción de hospitalización por insuficiencia cardíaca (HR 0.65; IC95% 0.50­0.85; p=0.002), de la mortalidad cardiovascular (HR 0,62; IC95% 0,49­0,77) y de la mortalidad general (HR 0,68; IC95% 0,57­0,82; p=0,001). En el subgrupo de personas con diabetes que no usaban insulina, hubo beneficio con empagliflozina con relación al desenlace primario (HR 0.79; IC95% 0.64­0.97; DR 2.5; NNT 40) y a muertes de causa cardiovascular (HR 0.61; IC95% 0.44­0.85; DR 2; NNT 49). No hubo diferencia significativa con relación al placebo para accidentes cerebrovasculares fatal y no fatal, tampoco en el resultado compuesto de accidente cerebrovascular debilitante no fatal y fatal (HR 0.81; IC95% 0.43­1.50; p=0.50). Hubo más personas acometidas por accidente cerebrovascular en el grupo intervención en que la hemoglobina glicada inicial era un 8,5%, favoreciendo el placebo (p=0.01). Conclusión: Los datos encontrados favorecen el beneficio de utilizar ese medicamento en el Sistema Único de Salud en personas con enfermedad cardiovascular. Entretanto ha habido heterogeneidad entre los grupos de población, lo que puede ayudar a delinear qué estrategias de uso para estos medicamentos. Son necesarios más estudios para evaluar cuál sería el motivo de no haber beneficio en resultados cerebrovasculares aisladamente.


Subject(s)
Cardiovascular Diseases , Diabetes Mellitus, Type 2 , Glucagon-Like Peptide 1 , Sodium-Glucose Transporter 2 Inhibitors
11.
Int. j. cardiovasc. sci. (Impr.) ; 35(1): 95-106, Jan.-Feb. 2022. tab, graf
Article in English | LILACS | ID: biblio-1356307

ABSTRACT

Abstract Background: Type 2 diabetes mellitus (T2DM) is an independent risk factor for cardiovascular impairment, increasing the rates of atherosclerotic and non-atherosclerotic events. Additionally, adverse kidney events are directly linked with T2DM and cardiovascular diseases. In this context, the sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated both cardioprotective and renoprotective effects in patients with or without T2DM. Therefore, the present meta-analysis aims to evaluate cardiovascular outcomes involving SGLT2i as monotherapy or other add-on antidiabetic agents (ADA) in patients with or without T2DM. Objetive: The present meta-analysis aims to evaluate cardiovascular outcomes involving SGLT2i as monotherapy or add-on other ADA in patients with or without T2DM. Methods: The entrance criteria to SGLT2i studies were: describing any data regarding cardiovascular effects; enrolling more than 1,000 participants; being approved by either the FDA or the EU, and having available access to the supplementary data. The trial had to exhibit at least one of the following results: major adverse cardiovascular events (MACE), cardiovascular death or hospitalization for heart failure, cardiovascular death, hospitalization for heart failure, renal or cardiovascular adverse events, or non-cardiovascular death. The significance level of 0.05 was adopted in the statistical analysis. Results: Nine trials with a total of 76,285 participants were included in the meta-analysis. SGLT2i reduced MACE (RR 0.75, 95% CI [0.55-1.01]), cardiovascular death or hospitalization for heart failure (RR 0.72, 95% CI [0.55-0.93]), cardiovascular death (RR 0.66, 95% CI [0.48-0.91]), hospitalization for heart failure (RR 0.58, 95% CI [0.46-0.73]), renal or cardiovascular adverse events (RR 0.55, 95% CI [0.39-0.78]), and non-cardiovascular death (RR 0.88, 95% CI [0.60-1.00]). Conclusions: Conjunction overall data suggests that these drugs can minimize the risk of cardiovascular events, thus decreasing mortality in patients, regardless of the presence of T2DM.


Subject(s)
Humans , Cardiotonic Agents , Cardiovascular Diseases/mortality , Cardiovascular Diseases/drug therapy , Diabetes Mellitus, Type 2 , Sodium-Glucose Transporter 2 Inhibitors/therapeutic use , Reproducibility of Results , Outcome Assessment, Health Care , Sodium-Glucose Transporter 2 , Hospitalization , Kidney Diseases/drug therapy
12.
Arch. endocrinol. metab. (Online) ; 66(1): 32-39, Jan.-Feb. 2022. tab
Article in English | LILACS | ID: biblio-1364313

ABSTRACT

ABSTRACT Objetivo: Maturity onset diabetes of the young (MODY) patients have clinical heterogeneity as shown by many studies. Thus, often it is misdiagnosed to type 1 or type 2 diabetes(T2DM). The aim of this study is to evaluate MODY mutations in adult T2DM patients suspicious in terms of MODY, and to show clinical and laboratory differences between these two situations. Subjects and methods: In this study, we analyzed 72 type 2 diabetic patients and their relatives (35F/37M) who had been suspected for MODY and referred to genetic department for mutation analysis. The gene mutations for MODY have been assessed in the laboratory of Marmara University genetics. Totally 67 (32F/35M; median age 36.1) diabetic patients were analyzed for 7 MODY mutations. Twelve patients who have uncertain mutation (VUS) were excluded from study for further evaluation. MODY(+) (n:30) patients and T2DM patients (n:25) were compared for clinical and laboratory parameters. Results: In MODY(+) subjects, mutations in GCK (MODY 2) (n:12; 40%) were the most common followed by HNF4A (MODY 1) (n:4; 13.3%). Diabetes diagnosis age was younger in MODY(+) group but not statistically significant. Sixty-six percent of MODY(+) subjects had diabetes history at 3-consecutive generations in their family compared with 28% of T2DM patients statistically significant (p:0.006). Gender, BMI, C-peptide, HbA1c, lipid parameters, creatinine, GFR, microalbuminuria, vitamin D and calcium were not statistically different between the groups. Conclusion: According to present study results, MODY mutation positivity is most probable in young autoantibody (-) diabetic patients diagnosed before 30 years of age, who have first degree family history of diabetes.


Subject(s)
Humans , Adult , Diabetes Mellitus, Type 2/diagnosis , Diabetes Mellitus, Type 2/genetics , C-Peptide , Hepatocyte Nuclear Factor 1-alpha/genetics , Mutation/genetics
13.
Arch. endocrinol. metab. (Online) ; 66(1): 12-18, Jan.-Feb. 2022. tab
Article in English | LILACS | ID: biblio-1364310

ABSTRACT

ABSTRACT Objective: The AKR1B1 gene encodes an enzyme that catalyzes the reduction of glucose into sorbitol. Chronic hyperglycemia in patients with diabetes mellitus (DM) leads to increased AKR1B1 affinity for glucose and, consequently, sorbitol accumulation. Elevated sorbitol increases oxidative stress, which is one of the main pathways related to chronic complications of diabetes, including diabetic kidney disease (DKD). Accordingly, some studies have suggested the rs759853 polymorphism in the AKR1B1 gene is associated with DKD; however, findings are still contradictory. The aim was to investigate the association of the rs759853 polymorphism in the AKR1B1 gene and DKD. Materials and methods: The sample comprised 695 patients with type 2 DM (T2DM) and DKD (cases) and 310 patients with T2DM of more than 10 years' duration, but no DKD (controls). The polymorphism was genotyped by real-time PCR. Results: Allelic and genotype frequencies of this polymorphism did not differ significantly between groups. However, the A/A genotype was associated with risk for DKD after adjustment for gender, triglycerides, BMI, presence of hypertension and diabetic retinopathy, and duration of DM, under both recessive (P = 0.048) and additive (P = 0.037) inheritance models. Conclusion: Our data suggest an association between the AKR1B1 rs759853A/A genotype and risk for DKD in Brazilians T2DM patients.


Subject(s)
Humans , Aldehyde Reductase/genetics , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/genetics , Diabetic Nephropathies/complications , Diabetic Nephropathies/genetics , Case-Control Studies , Genetic Predisposition to Disease , Polymorphism, Single Nucleotide , Alleles , Gene Frequency , Genotype
14.
Arch. endocrinol. metab. (Online) ; 66(1): 40-49, Jan.-Feb. 2022. tab, graf
Article in English | LILACS | ID: biblio-1364307

ABSTRACT

ABSTRACT Objectives: To describe the oral health profile and evaluate the impact of tooth loss on diet quality and glycemic control among 66 patients with type 2 diabetes (T2DM) treated in an endocrinology outpatient clinic at a teaching hospital. Materials and methods: Questionnaires about diabetes self-care (SDSCA), masticatory ability, diet quality, anxiety level about dental treatment, and oral health were applied. Laboratory tests were retrieved from medical records or newly collected samples. Results: The presence of fewer than 21 teeth was associated with an unsatisfactory self-perceived masticatory ability (r = 0.44; p = 0.007). Most participants reported not having received guidance on oral health from their endocrinologists (81.8%) and having had the last visit to the dentist 2 years or more before the study (36.8%). The mean HbA1c level in the group with fewer than 21 teeth was comparable to that in the group with functional dentition (8.9 ± 1.5 and 8.7 ± 1.6%, respectively; p = 0.60). Conclusion: Adults with T2DM have a high prevalence of tooth loss and lack of information about oral hygiene care. Our results reinforce the need for more effective communication between medical and dental care teams.


Subject(s)
Humans , Adult , Diabetes Mellitus, Type 2 , Self Care , Oral Health , Diet , Glycemic Control
15.
Arch. endocrinol. metab. (Online) ; 66(1): 68-76, Jan.-Feb. 2022. tab, graf
Article in English | LILACS | ID: biblio-1364297

ABSTRACT

ABSTRACT The lowest dosage of empagliflozin (10 mg) showed similar benefits on glycated hemoglobin (HbA1c) level, body weight, blood pressure, and total and cardiovascular mortality in comparison with the highest available dose (25 mg) in the EMPAREG trial. These findings have not been clearly demonstrated for canagliflozin and dapagliflozin. The objective was to compare the effect of different doses of SGLT2 inhibitors commercially available in Brazil on HbA1c and body weight of patients with type 2 diabetes. MEDLINE, Cochrane and Embase databases were searched from inception until 11th October 2021 for randomized controlled trials of SGLT2 inhibitors in type 2 diabetes patients, lasting at least 12 weeks. HbA1c and body weight variations were described using standard mean difference. We performed direct and indirect meta-analysis, as well as a meta-regression with medication doses as covariates. Eighteen studies were included, comprising 16,095 patients. In the direct meta-analysis, SGLT2 inhibitors reduced HbA1c by 0.62% (95% CI −0.66 to −0.59) and body weight by 0.60 kg (95% CI −0.64 to −0.55). In the indirect meta-analysis, canagliflozin 300 mg ranked the highest regarding reductions in HbA1c and body weight. The remaining medications and dosages were clinically similar, despite some statistically significant differences among them. Canagliflozin 300 mg seems to be more potent in reducing HbA1c and body weight in patients with type 2 diabetes. The remaining SGLT2 inhibitors at different doses lead to similar effects for both outcomes. Whether these glycemic and weight effects are reflected in lower mortality and cardiovascular events is still uncertain and may be a topic for further studies.


Subject(s)
Humans , Diabetes Mellitus, Type 2/drug therapy , Sodium-Glucose Transporter 2 Inhibitors/therapeutic use , Hypoglycemic Agents/therapeutic use , Blood , Body Weight , Brazil , Glycated Hemoglobin A/analysis , Randomized Controlled Trials as Topic , Canagliflozin/therapeutic use
16.
Rev. méd. Chile ; 150(1): 46-53, ene. 2022. ilus, tab
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1389617

ABSTRACT

BACKGROUND: Osteoarthritis (OA) is a health problem affecting millions of individuals worldwide. Aim: To evaluate risk factors for hip and knee osteoarthritis (OA) in women aged 40 to 59 years. MATERIAL AND METHODS: Analysis of a prospective cohort of 1159 women attending preventive health care programs and followed during 28 years. They underwent a clinical and laboratory evaluation from 1990 to 1993. The diagnosis of OA was retrieved from registries of a special program for osteoarthritis in 2020. RESULTS: Twenty four percent of participants developed osteoarthritis during the follow-up. At the beginning of the study and compared with women without OA, they were older (median [interquartile range or IQR]: 49.6 [8.5] and 47.2 [8.2] years respectively), had a higher body mass index (26.3 [5.3] and 25.1 [5.3] respectively), and a higher frequency of jobs with low qualification (76 and 62% respectively). The presence of type 2 diabetes mellitus, chronic hypertension, a previous history of alcohol or cigarette consumption, postmenopausal status and lipid and glucose blood levels did not differ between women with or without OA. Cox regression showed a final model that incorporates body mass index (hazard ratio (HR): 1.04; 95% confidence intervals (CI): 1.01-1.07), age (HR: 1.05; 95% CI: 1.03-1.08) and having an unqualified job (HR: 1.88; 95% CI: 1.43-2.47) as risk factors for OA. CONCLUSIONS: Obesity and the type of job are the most relevant risk factors found for OD: both may be modified with proper care.


Subject(s)
Humans , Female , Middle Aged , Osteoarthritis, Hip/diagnosis , Osteoarthritis, Hip/etiology , Osteoarthritis, Hip/epidemiology , Osteoarthritis, Knee/etiology , Osteoarthritis, Knee/epidemiology , Diabetes Mellitus, Type 2/complications , Prospective Studies , Risk Factors
17.
Rev. méd. Chile ; 150(1): 17-22, ene. 2022. ilus, tab
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1389610

ABSTRACT

BACKGROUND: Hypertension and diabetes are highly prevalent conditions in Chilean adults. AIM: To describe the demographic and clinical profiles, risk factors and complications associated with arterial hypertension (AH) and diabetes mellitus (DM) in patients ascribed to a cardiovascular health program at a public primary health care center in Santiago. MATERIAL AND METHODS: Review of medical records of 583 patients aged 37 to 95 years (56% women). Gender, age, smoking habits, blood pressure, glycated hemoglobin levels, LDL cholesterol and triglycerides levels, nutritional status in the last control carried out, and associated cardiovascular complications were recorded. RESULTS: Thirty four percent (201 participants) and 36% (210 participants) had a decompensated DM and AH, respectively. Dyslipidemia was the main associated cardiovascular risk factor. The prevalence of obesity was 43% (249 participants). Twenty percent had chronic kidney disease and 13% had diabetic retinopathy. CONCLUSIONS: These patients have a high frequency of obesity, dyslipidemia, and chronic kidney disease.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Cardiovascular Diseases/etiology , Cardiovascular Diseases/epidemiology , Diabetes Mellitus, Type 2 , Diabetic Retinopathy/complications , Renal Insufficiency, Chronic , Dyslipidemias , Hypertension/complications , Hypertension/epidemiology , Primary Health Care , Chile/epidemiology , Prevalence , Risk Factors , Obesity/complications , Obesity/epidemiology
18.
Journal of Integrative Medicine ; (12): 193-203, 2022.
Article in English | WPRIM | ID: wpr-929228

ABSTRACT

Metabolic syndrome (MS) involves people with the following risk factors: obesity, hypertension, high glucose level and hyperlipidemia. It can increase the risk of heart disease, stroke and type 2 diabetes mellitus. The prevalence of MS in the world's adult population is about 20%-25%. Today, there is much care to use medicinal plants. Turmeric (Curcuma longa) as well as curcumin which is derived from the rhizome of the plant, has been shown beneficial effects on different components of MS. Thus, the purpose of this manuscript was to introduce different in vitro, in vivo and human studies regarding the effect of turmeric and its constituent on MS. Moreover, different mechanisms of action by which this plant overcomes MS have been introduced. Based on studies, turmeric and its bioactive component, curcumin, due to their anti-inflammatory and antioxidant properties, have antidiabetic effects through increasing insulin release, antihyperlipidemic effects by increasing fatty acid uptake, anti-obesity effects by decreasing lipogenesis, and antihypertensive effects by increasing nitric oxide. According to several in vivo, in vitro and human studies, it can be concluded that turmeric or curcumin has important values as a complementary therapy in MS. However, more clinical trials should be done to confirm these effects.


Subject(s)
Curcuma , Curcumin/therapeutic use , Diabetes Mellitus, Type 2/drug therapy , Humans , Metabolic Syndrome/drug therapy , Plant Extracts/therapeutic use , Rhizome
19.
Frontiers of Medicine ; (4): 17-24, 2022.
Article in English | WPRIM | ID: wpr-929201

ABSTRACT

Obesity is an important risk factor of type 2 diabetes (T2D), which has become an important factor threatening human health. However, no perfect drug choice for obesity exists. Semaglutide is a kind of human glucagon-like peptide-1 (GLP-1) analog that promotes insulin secretion while inhibiting glucagon secretion through a glucose concentration-dependent mechanism. GLP-1 can also delay stomach emptying and suppress appetite to help lose weight. This review summarizes clinical evidence of the semaglutide effect on T2D and obesity and establishes expectations on future clinical trials for obesity treatment.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Glucagon-Like Peptide-1 Receptor/therapeutic use , Glucagon-Like Peptides , Humans , Hypoglycemic Agents/therapeutic use , Motivation , Obesity/drug therapy
20.
Frontiers of Medicine ; (4): 126-138, 2022.
Article in English | WPRIM | ID: wpr-929192

ABSTRACT

This cross-sectional study aimed to investigate the quality of care of diabetes in Shanghai, China. A total of 173 235 patients with type 2 diabetes in 2017 were included in the analysis. Profiles of risk factors and intermediate outcomes were determined. The patients had a mean age of 66.43 ± 8.12 (standard deviation (SD)) years and a mean diabetes duration of 7.95 ± 5.53 (SD) years. The percentage of patients who achieved the target level for HbA1c (< 7.0%) was 48.6%. Patients who achieved the target levels for blood pressure (BP) < 130/80 mmHg and low-density lipoprotein-cholesterol (LDL-c) < 2.6 mmol/L reached 17.5% and 34.0%, respectively. A total of 3.8% achieved all three target levels, and the value increased to 6.8% with an adaptation of the BP target level (< 140/90 mmHg) for those over 65 years. Multivariable analysis identified the factors associated with a great likelihood of achieving all three target levels: male, young age, short diabetes duration, low body mass index, macrovascular complications, no microvascular complications, prescribed with lipid-lowering medication, and no prescription of antihypertensive medication. In conclusion, nearly 50% and one-third of the patients with diabetes met the target levels for HbA1c and LDL-c, respectively, with a low percentage achieving the BP target level. The percentage of patients who achieved all three target levels needs significant improvement.


Subject(s)
Aged , Blood Pressure , China/epidemiology , Cholesterol, LDL/therapeutic use , Cross-Sectional Studies , Diabetes Mellitus, Type 2/drug therapy , Glycated Hemoglobin A/analysis , Humans , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL